Common Bile Duct Diseases: Clinical Trials

3 trials for Common Bile Duct Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 withdrawn. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 2, Withdrawn 1

Follow Common Bile Duct Diseases: new trials by email Literature Review of Common Bile Duct Diseases trials Research Report on Common Bile Duct Diseases

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers
4-MUST - Chronic Cholecystitis, Biliary Dyskinesia
Phase 1RecruitingValenta Pharm JSC452026-01-262026-06-15
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Trimedat® - Irritable Bowel Syndrome, Gallstone Disease
Phase 1RecruitingValenta Pharm JSC362025-11-062026-02-19
Transvaginal Cholecystectomy Using Endoscopic Assistance
cholecystectomy. - Cholelithiasis, Cholecystitis
Phase 1WithdrawnUniversity of Missouri-Columbia2009-01-012016-09-30

Narrower conditions

Biliary Dyskinesia (3)  ·  Cholelithiasis (2)  ·  Cholecystitis (1)  ·  Gastroesophageal Reflux (1)  ·  Irritable Bowel Syndrome (1)  ·  Postcholecystectomy Syndrome (1)

Broader conditions

Bile Duct Diseases (3)  ·  Biliary Tract Diseases (3)  ·  Digestive System Diseases (3)  ·  Colonic Diseases (1)  ·  Colonic Diseases, Functional (1)  ·  Deglutition Disorders (1)  ·  Esophageal Diseases (1)  ·  Esophageal Motility Disorders (1)  ·  Gallbladder Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Intestinal Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Postoperative Complications (1)

Interventions

Cholecystectomy (1)  ·  Trimebutine (1)

Sponsors

Valenta Pharm JSC (2)  ·  University of Missouri-Columbia (1)

Countries

Russia (2)

Top investigators

Brent Miedema, MD (1)